Education
About Us
Working with TipRanks
Follow Us
Grace Therapeutics (GRCE)
NASDAQ:GRCE
Total Valuation
Grace Therapeutics has a market cap or net worth of $40.88M. The enterprise value is -$622.90K.
Market Cap$40.88M
Enterprise Value-$622.90K
Share Statistics
Grace Therapeutics has 13,718,106 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding13,718,106
Owned by Insiders9.57%
Owned by Institutions23.22%
Financial Efficiency
Grace Therapeutics’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -15.71%.
Return on Equity (ROE)-0.21
Return on Assets (ROA)-0.18
Return on Invested Capital (ROIC)-15.71%
Return on Capital Employed (ROCE)-0.18
Revenue Per Employee0.00
Profits Per Employee-3.21M
Employee Count4
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Grace Therapeutics is -1.74. Grace Therapeutics’s PEG ratio is 0.02.
PE Ratio-1.74
PS Ratio0.00
PB Ratio0.36
Price to Fair Value0.36
Price to FCF-1.81
Price to Operating Cash Flow-1.81
PEG Ratio0.02
Income Statement
In the last 12 months, Grace Therapeutics had revenue of 0.00 and earned -12.85M in profits. Earnings per share was -1.73.
Revenue0.00
Gross Profit0.00
Operating Income-12.85M
Pretax Income-14.69M
Net Income-12.85M
EBITDA-11.33M
Earnings Per Share (EPS)-1.73
Cash Flow
In the last 12 months, operating cash flow was -14.04M and capital expenditures -22.00K, giving a free cash flow of -14.06M billion.
Operating Cash Flow-14.04M
Free Cash Flow-14.06M
Free Cash Flow per Share-1.02
Dividends & Yields
Grace Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.05
52-Week Price Change-9.60%
50-Day Moving Average2.59
200-Day Moving Average3.03
Relative Strength Index (RSI)50.56
Average Volume (3m)30.99K
Important Dates
Grace Therapeutics upcoming earnings date is Jun 24, 2025, TBA Not Confirmed.
Last Earnings DateFeb 13, 2025
Next Earnings DateJun 24, 2025
Ex-Dividend Date―
Financial Position
Grace Therapeutics as a current ratio of 14.26, with Debt / Equity ratio of 0.00%
Current Ratio14.26
Quick Ratio14.26
Debt to Market Cap0.00
Net Debt to EBITDA2.03
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Grace Therapeutics has paid -1.83M in taxes.
Income Tax-1.83M
Effective Tax Rate0.12
Enterprise Valuation
Grace Therapeutics EV to EBITDA ratio is 0.05, with an EV/FCF ratio of 0.05.
EV to Sales0.00
EV to EBITDA0.05
EV to Free Cash Flow0.05
EV to Operating Cash Flow0.05
Balance Sheet
Grace Therapeutics has $11.05M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$11.05M billion.
Cash & Marketable Securities$11.05M
Total Debt$0.00
Net Cash-$11.05M
Net Cash Per Share-$0.81
Tangible Book Value Per Share$1.68
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Grace Therapeutics is $11.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$11.50
Price Target Upside293.84% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast75.74%